diff --git a/content/news/2022-07-15-SPLOPBAN.md b/content/news/2022-07-15-SPLOPBAN.md
index c22508434..6a4b8d8fd 100644
--- a/content/news/2022-07-15-SPLOPBAN.md
+++ b/content/news/2022-07-15-SPLOPBAN.md
@@ -4,6 +4,7 @@ authors = ["Ed Mahon"]
blurb = "A federal lawsuit alleges the Pennsylvania court system discriminated against people with opioid use disorder, raising questions about who is responsible for decisions made by local judges."
byline = "Ed Mahon of Spotlight PA"
description = "A federal lawsuit alleges the Pennsylvania court system discriminated against people with opioid use disorder, raising questions about who is responsible for decisions made by local judges."
+feed-exclude = false
image = "external/0xw0tndqfe9xz56gcxmj1ev4wc.jpeg"
image-credit = "Kent M. Wilhelm / Spotlight PA"
image-description = "The Justice Department sued the Pennsylvania court system in February, alleging that it discriminated against people with opioid use disorder."
@@ -12,6 +13,7 @@ internal-id = "SPLOPBAN"
kicker = "Health"
modal-exclude = false
no-index = false
+pinned = false
published = 2022-07-15T05:00:35-04:00
slug = "pa-court-lawsuit-opioid-medication-discrimination"
suppress-date = false
@@ -39,7 +41,7 @@ Three drugs — methadone, buprenorphine, and extended-release naltrexone — ar
For people with opioid use disorder, buprenorphine and methadone can reduce withdrawal symptoms and cravings without causing a euphoric high, according to a report from the National Institute on Drug Abuse, a federal agency. The medications allow patients to “function normally, attend school or work, and participate in other forms of treatment,” the report says.
-The third drug, naltrexone, works to block the euphoric effects of opioid drugs, and the federal Substance Abuse and Mental Health Services Administration has found there is “no abuse and diversion potential with naltrexone.”
+The third drug, naltrexone, works to block the euphoric effects of opioid drugs, and the federal Substance Abuse and Mental Health Services Administration has found there is “no abuse and diversion potential with naltrexone.”
## What does the Department of Justice allege?